Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Long-Term Natural History of Microscopic Colitis: A Population-Based Cohort

J. Loreau, D. Duricova, C. Gower-Rousseau, G. Savoye, O. Ganry, H. Ben Khadhra, H. Sarter, C. Yzet, JP. Le Mouel, M. Kohut, F. Brazier, D. Chatelain, E. Nguyen-Khac, JL. Dupas, M. Fumery,

. 2019 ; 10 (9) : e00071. [pub] -

Language English Country United States

Document type Journal Article

OBJECTIVES: Data on long-term natural history of microscopic colitis (MC), including collagenous (CC) and lymphocytic colitis (LC), are lacking. METHODS: All new cases of MC diagnosed in the Somme area, France, between January 1, 2005, and December 31, 2007, were prospectively included. Colonic biopsies from all patients were reviewed by a group of 4 gastrointestinal pathologist experts to assess the diagnosis of CC or LC. Demographic and clinical data were retrospectively collected from diagnosis to February 28, 2017. RESULTS: One hundred thirty cases of MC, 87 CC and 43 LC, were included (median age at diagnosis: 70 [interquartile range, 61-77] and 48 [IQR, 40-61] years, respectively). The median follow-up was 9.6 years (7.6; 10.6). By the end of the follow-up, 37 patients (28%) relapsed after a median time of 3.9 years (1.2; 5.0) since diagnosis, without significant difference between CC and LC (30% vs 26%; P = 0.47). Twenty patients (15%) were hospitalized for a disease flare, and 32 patients (25%) presented another autoimmune disease. Budesonide was the most widely used treatment (n = 74, 59%), followed by 5-aminosalicylic acid (n = 31, 25%). The median duration of budesonide treatment was 92 days (70; 168), and no adverse event to budesonide was reported. Sixteen patients (22%) developed steroid dependency and 4 (5%) were corticoresistant. No difference in the risk of digestive and extradigestive cancer was observed compared with the general population. None of the death (n = 25) observed during the follow-up were linked to MC. In multivariate analysis, age at diagnosis (HR, 1.03; 95% confidence interval, 1.00-1.06; P = 0.02) and budesonide exposure (HR, 2.50; 95% confidence interval, 1.11-5.55; P = 0.03) were significantly associated with relapse. DISCUSSION: This population-based study showed that after diagnosis, two-third of the patients with MC observed long-term clinical remission. Age at diagnosis and budesonide exposure were associated with a risk of relapse.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025681
003      
CZ-PrNML
005      
20201222155343.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.14309/ctg.0000000000000071 $2 doi
035    __
$a (PubMed)31478957
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Loreau, Julien $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France.
245    10
$a Long-Term Natural History of Microscopic Colitis: A Population-Based Cohort / $c J. Loreau, D. Duricova, C. Gower-Rousseau, G. Savoye, O. Ganry, H. Ben Khadhra, H. Sarter, C. Yzet, JP. Le Mouel, M. Kohut, F. Brazier, D. Chatelain, E. Nguyen-Khac, JL. Dupas, M. Fumery,
520    9_
$a OBJECTIVES: Data on long-term natural history of microscopic colitis (MC), including collagenous (CC) and lymphocytic colitis (LC), are lacking. METHODS: All new cases of MC diagnosed in the Somme area, France, between January 1, 2005, and December 31, 2007, were prospectively included. Colonic biopsies from all patients were reviewed by a group of 4 gastrointestinal pathologist experts to assess the diagnosis of CC or LC. Demographic and clinical data were retrospectively collected from diagnosis to February 28, 2017. RESULTS: One hundred thirty cases of MC, 87 CC and 43 LC, were included (median age at diagnosis: 70 [interquartile range, 61-77] and 48 [IQR, 40-61] years, respectively). The median follow-up was 9.6 years (7.6; 10.6). By the end of the follow-up, 37 patients (28%) relapsed after a median time of 3.9 years (1.2; 5.0) since diagnosis, without significant difference between CC and LC (30% vs 26%; P = 0.47). Twenty patients (15%) were hospitalized for a disease flare, and 32 patients (25%) presented another autoimmune disease. Budesonide was the most widely used treatment (n = 74, 59%), followed by 5-aminosalicylic acid (n = 31, 25%). The median duration of budesonide treatment was 92 days (70; 168), and no adverse event to budesonide was reported. Sixteen patients (22%) developed steroid dependency and 4 (5%) were corticoresistant. No difference in the risk of digestive and extradigestive cancer was observed compared with the general population. None of the death (n = 25) observed during the follow-up were linked to MC. In multivariate analysis, age at diagnosis (HR, 1.03; 95% confidence interval, 1.00-1.06; P = 0.02) and budesonide exposure (HR, 2.50; 95% confidence interval, 1.11-5.55; P = 0.03) were significantly associated with relapse. DISCUSSION: This population-based study showed that after diagnosis, two-third of the patients with MC observed long-term clinical remission. Age at diagnosis and budesonide exposure were associated with a risk of relapse.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a kohortové studie $7 D015331
650    _2
$a kolitida mikroskopická $x komplikace $x diagnóza $x terapie $7 D046728
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a recidiva $7 D012008
650    _2
$a časové faktory $7 D013997
655    _2
$a časopisecké články $7 D016428
700    1_
$a Duricova, Dana $u ISCARE I.V.F. a.s., IBD Clinical and Research Center, Prague, Czech Republic.
700    1_
$a Gower-Rousseau, Corinne $u Lille University and Hospital, Public Health, Epidemiology and Economic Health, Registre Epimad, Maison Régionale de la Recherche Clinique, Lille, France. Lille University, Inserm, LIRIC Unit UMR 995 Team 5, Faculté de Médecine, Lille, France.
700    1_
$a Savoye, Guillaume $u Gastroenterology Unit, Hôpital Charles Nicolle, Rouen University Hospital, Epimad, Registry, Rouen, France.
700    1_
$a Ganry, Olivier $u Cancer Registry of the Somme-Inserm EA-DGS EA 4666 Epidemiology and Public Health Service, Amiens University Hospital, Amiens, France.
700    1_
$a Ben Khadhra, Hajer $u Cancer Registry of the Somme-Inserm EA-DGS EA 4666 Epidemiology and Public Health Service, Amiens University Hospital, Amiens, France.
700    1_
$a Sarter, Hélène $u Lille University and Hospital, Public Health, Epidemiology and Economic Health, Registre Epimad, Maison Régionale de la Recherche Clinique, Lille, France. Lille University, Inserm, LIRIC Unit UMR 995 Team 5, Faculté de Médecine, Lille, France.
700    1_
$a Yzet, Clara $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France.
700    1_
$a Le Mouel, Jean-Philippe $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France.
700    1_
$a Kohut, Mathieu $u Clinique Sainte Isabelle, Abbeville, France.
700    1_
$a Brazier, Franck $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France.
700    1_
$a Chatelain, Denis $u Department of Pathology, Amiens University Hospital, Amiens, France.
700    1_
$a Nguyen-Khac, Eric $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France.
700    1_
$a Dupas, Jean-Louis $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France.
700    1_
$a Fumery, Mathurin $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France.
773    0_
$w MED00194310 $t Clinical and translational gastroenterology $x 2155-384X $g Roč. 10, č. 9 (2019), s. e00071
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31478957 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155338 $b ABA008
999    __
$a ok $b bmc $g 1599826 $s 1116367
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 10 $c 9 $d e00071 $e - $i 2155-384X $m Clinical and translational gastroenterology $n Clin Transl Gastroenterol $x MED00194310
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...